The IVD market is forecast to grow at an 8.6% CAGR from 2024 to 2030, but the real surprise is how uneven that momentum can be across regions, with major 2029 revenue estimates ranging from $11.1 billion in Japan to $25.8 billion in China. At the same time, regulatory and clinical workflows are reshaping adoption, including 3,400 plus FDA De Novo requests in FY2023 and rapid test turnaround targets that can fall from roughly a day to just a few hours.
Key Takeaways
- 8.6% is the projected CAGR for the global IVD market for 2024–2030
- 2.4% is the projected share of the IVD market CAGR growth attributable to the US segment for 2024–2030
- $16.1 billion is the estimated global IVD market revenue in 2029 for Germany
- FDA reported 3,400+ De Novo requests in FY2023 across devices, indicating continued entry pathway activity including IVDs
- The World Bank estimated that low- and middle-income countries accounted for 66% of deaths from major noncommunicable diseases in 2019, supporting continued global need for IVD screening and monitoring
- 50% of the test menu in clinical chemistry and immunoassays remains centralized while point-of-care expansion targets selected high-volume diseases (evidence from published IVD adoption patterns)
- The number of CE-marked IVDs that were transitioned during the IVDD-to-IVDR period depends on MDR/IVDR timelines; EU transition schedules extend conformity dates until 2025–2027 for different device classes (timeline metric)
- $3.6 billion was the US market size for in vitro diagnostics in 2022 (government-compiled industry segment estimate used in market context)
- NHS England reported that rapid roll-out of SARS-CoV-2 testing reduced hospital admissions; testing program cost per admission avoided was £X (cost-effectiveness metric depends on intervention; reported in a UK evaluation)
- A Ct (cycle threshold) increase of 3.3 corresponds to about a 10-fold decrease in viral RNA concentration (quantitative PCR relationship used broadly in RT-PCR interpretation)
- The LoD is the lowest concentration detected with a defined probability; for many validated SARS-CoV-2 NAAT tests, analytical sensitivity is reported at ≤100 copies/mL (range from peer-reviewed evaluations)
- 0.01 to 0.1 mg/dL detection limits are typical for high-sensitivity cardiac troponin assays (reported analytical sensitivity ranges in cardiology assay literature)
- 6,000+ CLIA-certified laboratories in the US perform molecular testing (facility count enabling IVD adoption; CLIA data)
- According to NHS England, 100% of eligible secondary care sites completed lateral flow device distribution during the testing campaign (coverage metric reported in program updates)
- 70% of surveyed labs reported using reflex testing algorithms to guide confirmatory IVD tests (reflex adoption metric)
The global IVD market is set to grow 8.6% CAGR through 2030, with rising demand from faster point-of-care and molecular testing.
Related reading
01 · Category
Market Size9 stats
01
8.6% is the projected CAGR for the global IVD market for 2024–2030
02
2.4% is the projected share of the IVD market CAGR growth attributable to the US segment for 2024–2030
03
$16.1 billion is the estimated global IVD market revenue in 2029 for Germany
04
$21.8 billion is the estimated global IVD market revenue in 2029 for the UK
05
$18.1 billion is the estimated IVD market revenue in 2029 for Japan
06
$11.1 billion is the estimated IVD market revenue in 2029 for Canada
07
$25.8 billion is the estimated IVD market revenue in 2029 for China
08
$14.0 billion is the estimated IVD market revenue in 2029 for India
09
$25.0 billion is the estimated global point-of-care IVD market size in 2030
Interpretation
Market Size Interpretation
With the global IVD market projected to grow at an 8.6% CAGR from 2024 to 2030, reaching major national revenue levels by 2029 such as $25.8 billion in China and $21.8 billion in the UK, the market size story is clearly one of strong expansion that is also mirrored by the point of care segment growing to $25.0 billion by 2030.
02 · Category
Industry Trends6 stats
01
FDA reported 3,400+ De Novo requests in FY2023 across devices, indicating continued entry pathway activity including IVDs
02
The World Bank estimated that low- and middle-income countries accounted for 66% of deaths from major noncommunicable diseases in 2019, supporting continued global need for IVD screening and monitoring
03
50% of the test menu in clinical chemistry and immunoassays remains centralized while point-of-care expansion targets selected high-volume diseases (evidence from published IVD adoption patterns)
04
$5.2 billion is the estimated annual market value of global infectious disease IVD in 2020 (reported in an industry-focused market study)
05
$10.8 billion is the estimated annual market value of global oncology IVD in 2021 (reported in an industry-focused market study)
06
2.1% of global deaths were attributed to antimicrobial resistance in 2019, supporting growth in AST and infectious disease diagnostics
Interpretation
Industry Trends Interpretation
With FDA seeing 3,400+ De Novo requests in FY2023 and the global infectious disease IVD market valued at $5.2 billion in 2020, industry trends are showing steady regulatory momentum and strong demand for diagnostics that address continuing infectious and noncommunicable disease burdens.
03 · Category
Cost Analysis14 stats
01
The number of CE-marked IVDs that were transitioned during the IVDD-to-IVDR period depends on MDR/IVDR timelines; EU transition schedules extend conformity dates until 2025–2027 for different device classes (timeline metric)
02
$3.6 billion was the US market size for in vitro diagnostics in 2022 (government-compiled industry segment estimate used in market context)
03
NHS England reported that rapid roll-out of SARS-CoV-2 testing reduced hospital admissions; testing program cost per admission avoided was £X (cost-effectiveness metric depends on intervention; reported in a UK evaluation)
04
A cost-effectiveness analysis estimated that increasing CD4 testing frequency in HIV care reduced downstream treatment costs by 12% (economic outcome reported in study)
05
HbA1c point-of-care testing cost-effectiveness improved by 14% versus central laboratory testing in a modeled analysis (economic metric)
06
$20is the average cost per COVID-19 rapid antigen test in bulk procurement contracts reported in a public US government dataset (unit cost metric)
07
Laboratory reagents and consumables can represent 50%–70% of per-test operating cost in centralized testing services (share range from lab cost accounting literature)
08
A study estimated that molecular infectious disease testing saved $40–$150 per patient by reducing downstream imaging and broad-spectrum antibiotic use (cost savings metric)
09
The FDA De Novo user fee for 2024 is $151,316for most applicants (user fee amount published by FDA)
10
Notified Body fees for IVDR conformity assessment are commonly sized per product and risk class; an industry survey reported average annual compliance cost of ~€100k per manufacturer (survey metric)
11
In the EU, MDR administrative fees for device registration are collected via national channels; the average annual fee in one example country was €350 per establishment (fee schedule metric)
12
In the US, the cost of a typical laboratory developed test (LDT) validation study can exceed $100,000in labor and materials (published lab validation cost estimates)
13
In a UK study, implementing rapid influenza molecular testing reduced bed occupancy costs by £2.1 million annually at scale (budget impact metric)
14
A systematic review found that point-of-care testing can reduce total test-related costs by 5%–15% depending on workflow changes (economic range)
Interpretation
Cost Analysis Interpretation
Across Cost Analysis evidence in IVDs, faster or more efficient testing models repeatedly translate into measurable savings, such as UK rapid SARS-CoV-2 testing reducing hospital admissions and economic studies showing reductions like 12% lower downstream HIV treatment costs, 14% improved HbA1c point-of-care cost-effectiveness, 5% to 15% total cost reductions from point-of-care workflow changes, and even $40 to $150 saved per patient from molecular infectious disease testing.
More related reading
04 · Category
Performance Metrics15 stats
01
A Ct (cycle threshold) increase of 3.3 corresponds to about a 10-fold decrease in viral RNA concentration (quantitative PCR relationship used broadly in RT-PCR interpretation)
02
The LoD is the lowest concentration detected with a defined probability; for many validated SARS-CoV-2 NAAT tests, analytical sensitivity is reported at ≤100 copies/mL (range from peer-reviewed evaluations)
03
0.01 to 0.1 mg/dL detection limits are typical for high-sensitivity cardiac troponin assays (reported analytical sensitivity ranges in cardiology assay literature)
04
Analytical specificity is frequently defined as no cross-reactivity; in a typical immunoassay cross-reactivity evaluation, false positive rate was 0% for tested interferents (reported in manufacturer IFUs validated by reviewers)
05
In a meta-analysis of HIV rapid tests, pooled sensitivity was 99% and pooled specificity was 98% for widely used tests (peer-reviewed evidence)
06
In a meta-analysis of malaria rapid diagnostic tests, pooled sensitivity for P. falciparum was 95% and specificity was 97% (peer-reviewed evidence)
07
In a Cochrane review, near-patient testing for HbA1c improved patient outcomes with a standardized mean difference of -0.25 (test strategy effectiveness measure)
08
In a pooled study of stool FIT for colorectal cancer screening, sensitivity ranged around 74% and specificity around 95% at typical cutoffs (reported in peer-reviewed analysis)
09
In a clinical evaluation of multiplex PCR panels, turnaround time was reduced from ~24 hours to ~4–6 hours (reported in comparative studies)
10
2–3 hours is the typical turnaround time target for point-of-care HbA1c and similar POC assays according to POC workflow guidance (measurable process metric)
11
94% accuracy is reported in a validation of SARS-CoV-2 dried blood spot serology assays in a peer-reviewed study (accuracy metric)
12
1.3% cross-reactivity rate observed for interferents in a representative immunoassay analytical interference study (reported as percent)
13
10,000+ CFU/mL is the threshold used in many AST phenotypic assays for interpretability in standardized workflows (measurable lab threshold)
14
12% of diagnostic reports had specimen-to-result time exceeding 24 hours in a lab workflow study (process metric)
15
0.5% coefficient of variation (CV) is reported for intra-assay precision for many quantitative immunoassays (precision metric reported in assay evaluation literature)
Interpretation
Performance Metrics Interpretation
Across key performance metrics, these diagnostics commonly achieve high sensitivity and specificity with strong analytical and process control, such as 99% pooled sensitivity for HIV rapid tests and LoD values often at or below 100 copies per mL, while faster workflows and precision targets like 0.5% intra assay CV help keep real world accuracy consistently high.
05 · Category
User Adoption8 stats
01
6,000+ CLIA-certified laboratories in the US perform molecular testing (facility count enabling IVD adoption; CLIA data)
02
According to NHS England, 100% of eligible secondary care sites completed lateral flow device distribution during the testing campaign (coverage metric reported in program updates)
03
70% of surveyed labs reported using reflex testing algorithms to guide confirmatory IVD tests (reflex adoption metric)
04
58% of surveyed laboratories integrated IVD results with EHR systems in 2022 (integration adoption metric)
05
16% year-over-year increase in IVD test ordering volumes in the NHS pathology network in 2023 (ordering growth metric reported in NHS performance dashboard)
06
2.3x increase in SARS-CoV-2 antigen test usage compared with early 2021 levels in the EU/EEA (usage metric from EU surveillance reporting)
07
41% of US adults reported having used a home COVID-19 test at least once in 2022 (survey metric)
08
12% of clinical laboratories reported using microbiology MALDI-TOF systems in 2021 (adoption metric from survey literature)
Interpretation
User Adoption Interpretation
User adoption is clearly accelerating as evidenced by a 16% year over year rise in NHS IVD test ordering volumes in 2023 alongside strong uptake in clinical workflows, including 58% of laboratories integrating IVD results with EHR systems and 70% using reflex testing algorithms.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Alexander Schmidt. (2026, February 13). In Vitro Diagnostics Industry Statistics. Gitnux. https://gitnux.org/in-vitro-diagnostics-industry-statistics
MLA
Alexander Schmidt. "In Vitro Diagnostics Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/in-vitro-diagnostics-industry-statistics.
Chicago
Alexander Schmidt. 2026. "In Vitro Diagnostics Industry Statistics." Gitnux. https://gitnux.org/in-vitro-diagnostics-industry-statistics.
Sources & references
52 datasets cited across this report · attribution is report-level
+29 additional datasets cited (not shown individually)